Home › Compound Library › Ipamorelin
Growth hormone axis
Ipamorelin: How It Works, and What the Research Actually Shows
The short answer
Ipamorelin is a synthetic five-amino-acid peptide that switches on the same receptor as ghrelin, the hunger hormone, prompting the pituitary to release a pulse of growth hormone. What made it notable in 1998 was its selectivity: it raised growth hormone without the cortisol and prolactin rise seen with earlier compounds of its class. It is not FDA approved, and it is banned in sport.
Questions people ask about Ipamorelin
- What is ipamorelin?
- Does ipamorelin build muscle?
- Does ipamorelin burn fat?
- Ipamorelin vs sermorelin: what is the difference?
- Ipamorelin vs tesamorelin: which is better?
- Why is ipamorelin paired with CJC-1295?
- Does ipamorelin make you hungry?
- Does ipamorelin help with sleep?
- Is ipamorelin FDA approved?
- Is ipamorelin banned in sport?
Ipamorelin at a glance
| Also called | NNC 26-0161 |
|---|---|
| What it is | Synthetic pentapeptide (5 amino acids); growth hormone secretagogue |
| Acts on | GHS-R1a, the ghrelin receptor in the pituitary and hypothalamus |
| Main system | Growth hormone axis: body composition, recovery, sleep |
| Evidence level | Animal studies plus small human trials; no large outcome trials |
| FDA status (Sept 2026) | Not approved. On the FDA’s Category 2 bulk substances list, which bars compounding pharmacies from using it |
| In sport | Prohibited at all times (WADA S2.2.4, growth hormone secretagogues) |
What is ipamorelin?
Ipamorelin is a laboratory-made peptide of five amino acids. It belongs to a family called growth hormone secretagogues: compounds that ask the body to release more of its own growth hormone rather than supplying the hormone from outside.
It was described in 1998 by researchers at Novo Nordisk as “the first selective growth hormone secretagogue” (reference 1). Earlier compounds in the class raised growth hormone but dragged other hormones up with it. In animal studies, ipamorelin raised growth hormone without the increases in cortisol and ACTH that came with the older GHRPs.
Targeted Peptide Systems (pp. 131–132) places it in the growth hormone secretagogue category, and Metabolic Precision (pp. 126–127) treats it as the cleanest of the ghrelin-receptor compounds in the book.
How does ipamorelin work?
Growth hormone is not released steadily. It comes in pulses, mostly in the first hours of deep sleep, and two signals control the tap: GHRH opens it and somatostatin closes it. Ghrelin, made in the stomach, is a third signal that works through its own receptor, GHS-R1a.
Ipamorelin binds that ghrelin receptor. The pituitary responds with a pulse of growth hormone, which in turn drives IGF-1 production in the liver.
- It amplifies your own pulses rather than replacing the hormone, so the body’s feedback loops stay intact.
- Because it does not engage the GHRH receptor, it can be paired with a GHRH analog such as CJC-1295 for two different signals at once (Metabolic Precision, pp. 240–241).
- Unlike ghrelin itself, its appetite effect is modest, which is part of what “selective” means here.
Metabolic Precision (pp. 69–73) sets out what a working growth hormone axis does: fat release from tissue, lean mass preservation, collagen and tissue maintenance, and deeper slow-wave sleep.
What does the research show?
The founding study. Raun and colleagues, 1998, in European Journal of Endocrinology: ipamorelin produced a dose-dependent growth hormone release in animals with a selectivity profile no earlier secretagogue had (reference 1).
The human trial people rarely mention. The best-controlled human data is not about muscle at all. A randomised, placebo-controlled proof-of-concept trial published in 2014 tested ipamorelin for postoperative ileus, the gut shutdown that follows bowel surgery. It was a genuine clinical trial, and the compound did not go on to approval (reference 2).
Where the evidence stands. There is no large human trial of ipamorelin for body composition, recovery or ageing. The case rests on two things: growth hormone physiology, which is well established, and small studies and clinical reports, which are suggestive rather than conclusive. So the mechanism is solid, and the outcome data for this particular use is still being gathered — which is a different situation from evidence against it.
Side effects and cautions
The effects usually listed here belong to growth hormone itself, and the record for them comes largely from growth hormone given from outside the body, at exposures that carry blood levels above the range the body would produce on its own: fluid retention, tingling or numbness in the hands, joint aches, headache, and reduced insulin sensitivity in the short term (reference 5). Ipamorelin reaches growth hormone by a different route. It prompts the pituitary to release a pulse of your own, and that pulse is still subject to the feedback that normally limits it, so the physiological range is where the mechanism sits. Push past that range and the effects above become possibilities rather than a given, which is why blood sugar is the marker worth following and why monitoring belongs in the plan from the start.
Metabolic Precision (p. 73) adds the point most protocols miss: growth hormone compounds work poorly in a body that is insulin resistant or carrying a lot of visceral fat, because that state suppresses the growth hormone response in the first place. Correcting metabolism first is the book’s rule.
Anyone with active cancer, uncontrolled diabetes or a pituitary condition should not be using growth hormone secretagogues outside medical supervision. Product purity is a separate risk, since nothing sold for research use is made to medicine standards.
Is ipamorelin legal or FDA approved?
Not FDA approved for any use. It sits on the FDA’s Category 2 list of bulk drug substances, which bars compounding pharmacies from using it. It was reviewed again in 2024 and stayed there, and the July 2026 advisory committee meeting that recommended six other peptides did not cover ipamorelin (references 3, 4).
Banned in sport. The World Anti-Doping Agency prohibits growth hormone secretagogues at all times, in and out of competition, and names ipamorelin specifically (reference 6).
Status changes. This page is reviewed and updated as it does.
Ipamorelin vs sermorelin, tesamorelin and CJC-1295
These four get compared constantly, and the distinction is simple once you see it: which door they knock on.
- Ipamorelin works through the ghrelin receptor.
- Sermorelin, tesamorelin and CJC-1295 are GHRH analogs, working through the GHRH receptor.
- Tesamorelin is the only one of the four that is an approved medicine, for a specific condition (see our tesamorelin profile).
- CJC-1295 plus ipamorelin is the classic pairing because the two receptors are different, so the signals add rather than compete.
Metabolic Precision (pp. 240–241) makes the rule explicit: use one GHRH analog, optionally with one ghrelin-receptor compound. Two GHRH analogs together compete for the same receptor and gain nothing.
Risk, benefit, and the conversation this page is for
How to weigh it. Some research peptides have a quiet toxicology record, or an unfinished efficacy record. Ipamorelin is a different case: on its mechanism it genuinely moves physiology, and that is the reason to weigh it with due diligence rather than enthusiasm. Monitoring is paramount here, and the markers that matter are blood sugar, fluid balance, and IGF-1 itself for anyone with a cancer history.
The regulatory picture is moving, selectively. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. Ipamorelin was not among them. It sits in Category 2, barred from compounding. That is the same committee reaching a different conclusion about a different molecule. Reading those decisions one at a time is more useful than treating every compound outside the approved list as equivalent.
Why the class is taken seriously. The growth hormone axis is real, measurable physiology. So the question is not whether engaging it does anything. The question is whether you have done the due diligence to make an informed decision about engaging it at all: what your baseline looks like, what else you are taking, what you would measure along the way, and what would tell you to stop.
Which is the point of the series. Nothing here is a recommendation to use ipamorelin. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
Ipamorelin: frequently asked questions
What is ipamorelin?
A synthetic five-amino-acid peptide that stimulates the pituitary to release a pulse of growth hormone by acting on the ghrelin receptor. It is not an approved medicine.
Does ipamorelin build muscle?
The reasoning and the mechanism both point that way: ipamorelin raises growth hormone, and growth hormone supports lean mass. On that basis Metabolic Precision (pp. 69–73) treats body composition effects as a secondary layer rather than a primary driver.
Does ipamorelin burn fat?
Growth hormone increases the release of fat from tissue, which is why the class is studied for body composition, and the mechanism points in that direction. How much of it shows up in a given person is a separate question, and it turns on their own metabolic environment: insulin sensitivity, visceral fat, sleep and training all shape the response. That would be true of an average reported by a large trial as well, which is part of why Metabolic Precision (p. 73) puts correcting metabolism before adding a growth hormone compound.
Ipamorelin vs sermorelin: what is the difference?
They act on different receptors. Sermorelin is a GHRH analog; ipamorelin works through the ghrelin receptor. That is also why the two classes are sometimes combined rather than swapped.
Ipamorelin vs tesamorelin: which is better?
Better is the wrong axis, because they are not doing the same job. Tesamorelin is a GHRH analog and ipamorelin works through the ghrelin receptor, two different doors into the same axis, and on mechanism they complement each other rather than compete, which is the same logic behind the CJC-1295 pairing. That is a statement about mechanism, not a protocol suggestion. Tesamorelin is also the one of the two that is an approved medicine, for reducing excess abdominal fat in people with HIV-associated lipodystrophy, with Phase 3 data behind it (reference 7); ipamorelin is not approved and has no trial of that size behind it.
Why is ipamorelin paired with CJC-1295?
Because they use different receptors. CJC-1295 amplifies the GHRH signal, ipamorelin adds the ghrelin signal, so the two add up instead of competing. Evidence for the combination in people is limited.
Does ipamorelin make you hungry?
Much less than ghrelin itself. Selectivity is the reason it was developed, and reduced appetite stimulation compared with earlier secretagogues is part of that profile (reference 1).
Does ipamorelin help with sleep?
Growth hormone release and deep sleep are linked, and Metabolic Precision (p. 72) describes improved slow-wave sleep as one effect of growth hormone axis support.
Is ipamorelin FDA approved?
No. It is on the FDA’s Category 2 bulk substances list, which bars compounding pharmacies from using it (references 3, 4).
Is ipamorelin banned in sport?
Yes. Growth hormone secretagogues are prohibited at all times under WADA’s S2 category, with ipamorelin named (reference 6).
Where Ipamorelin appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how Ipamorelin fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Targeted Peptide Systems
Profile, growth hormone secretagogues · pp. 131–132
About the bookLook Inside
Books marked Look Inside include these exact pages in their free preview.
Related compounds
See how Ipamorelin fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. View sourceCited in Targeted Peptide Systems (p. 348), The Cognitive Advantage (p. 408), Metabolic Precision (p. 354) and Regenerative Resilience (p. 352)
- Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014;29(12):1527–1534. View source
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–177. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. View sourceCited in Metabolic Precision (p. 354) and The Longevity Map (p. 198)
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Ipamorelin is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.